MannKind Corporation (MNKD)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 4
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry.
Company overview
MannKind Corporation is a biopharmaceutical company focused on developing respiratory-delivered treatments for endocrine system disorders and rare lung conditions in the U.S. Its primary product is Afrezza, an inhaled insulin for diabetes management. The company also markets Thyquidity for hypothyroidism and collaborates with United Therapeutics and NRx Pharmaceuticals on various projects.
Fundamental
weakMannKind shows strong revenue growth but faces high leverage and negative equity, making its fundamentals speculative.
MannKind is scaling quickly (FY2025 revenue $349M, +22% YoY; ~46.65% 5-year CAGR) and gross margin remains strong (~75.96% TTM), supported by product portfolio expansion and a June 2026 FDA pediatric Afrezza approval (8-K). The trade-off is financial risk: the March 2026 10-Q reports ~$133.8M cash/investments but also substantial long-term debt, and leverage/coverage metrics are stressed (net debt/EBITDA ~13.93; interest coverage ~0.34) with negative equity. Result: solid commercial momentum, but elevated leverage and recent margin compression keep the fundamentals speculative.
Sentiment
fairSentiment is mildly bullish, supported by recent positive news on pediatric Afrezza expansion.
Near-term sentiment is mildly bullish, driven by MannKind’s 2026-06-23 Breakthrough T1D grant supporting the INHALE-1ST pediatric Afrezza trial (announced; likely partially priced). The 30–90d baseline coverage is sparse (delta indeterminate) and Reddit engagement couldn’t be scored due to rate limits, but legal/regulatory scans show no active investigations—leaving a constructive yet mid-conviction setup.
Technical
goodTechnical indicators confirm a strong uptrend, but caution is advised due to overbought conditions.
Chart quality is strong: MNKD is above all key moving averages and the daily VWAP, MACD is positive and above its signal, and ADX confirms a powerful uptrend. The main technical caution is short-term stretch after a sharp advance, with RSI and Williams %R near overbought levels, which raises chase risk even though the primary tape remains bullish.
You’re looking at 2026-07-02 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.